Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8752635 | 1.00 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL18892768 | 1.00 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL21202645 | 0.87 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL21474777 | 0.87 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL17754500 | 0.84 | SMPD1 (0.34) | SMPD1 | |
| SCHEMBL12090319 | 0.84 | SMPD1 (0.33) | SMPD1 | |
| SCHEMBL13830489 | 0.84 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL13912378 | 0.84 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL12523685 | 0.84 | SMPD1 (0.41) | SMPD1 | |
| SCHEMBL10005831 | 0.82 | FBP1 (0.34) | SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233741-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS, INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170145417-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS INC (US) | 2017-05-25 | — | — | US | disclosed |
| US-20160101128-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | IDERA PHARMACEUTICALS, INC. | 2016-04-14 | — | — | US | disclosed |
| US-8853375-B2 | Toll like receptor modulators | IDERA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853177-B2 | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto | IDERA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8426375-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8399423-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8188261-B2 | Stabilized immune modulatory RNA (SIMRA) compounds | IDERA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8106173-B2 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | IDERA PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110009477-A1 | OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS | IDERA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100098685-A1 | Use of Inhibitors of Toll-Like Receptors in the Prevention and Treatment of Hypercholesterolemia and Hyperlipidemia and Diseases Related Thereto | IDERA PHARMACEUTICALS, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20090098063-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090087388-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS, INC. | 2009-04-02 | — | — | US | disclosed |
| US-20090053205-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS | IDERA PHARMACEUTICALS, INC | 2009-02-26 | — | — | US | disclosed |
| US-20090053148-A1 | TOLL LIKE RECEPTOR MODULATORS | IDERA PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | IDERA PHARMACEUTICALS, INC. | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098685-A1 | Use of Inhibitors of Toll-Like Receptors in the Prevention and Treatment of Hypercholesterolemia and Hyperlipidemia and Diseases Related Thereto | TLR1, TLR4, TLR3 | SMPD1 2178/4885 |
| US-20170233741-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | TLR3, TLR9, TLR5 | SMPD1 3868/4885 |
| US-20160101128-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | TLR9, TLR3, TLR7 | SMPD1 1443/4885 |
| US-20110009477-A1 | OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS | TLR3, TLR9, TLR1 | SMPD1 2121/4885 |
| US-20090087388-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | TLR3, TLR9, TLR5 | SMPD1 3868/4885 |
| US-20170145417-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | TLR3, TLR9, TLR5 | SMPD1 3868/4885 |
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | TLR8, TLR7, TLR9 | SMPD1 404/4885 |
| US-20090098063-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | TLR3, TLR9, TLR1 | SMPD1 4555/4885 |
| US-20090053205-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS | TLR8, TLR7, TLR9 | SMPD1 476/4885 |
| US-20090053148-A1 | TOLL LIKE RECEPTOR MODULATORS | TLR9, TLR3, TLR5 | SMPD1 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.